

**REMARKS**

***Response to Restriction Requirement***

The Examiner requires restriction to one of the following two Groups:

- Group I:** Claims 1-18, drawn to a method for differentiation pluripotent stem cells into cardiomyocytes by culture with a BMP antagonist; or
- Group II:** Claims 1, 3-12, and 14-18, drawn to a method for differentiation multipotent adult stem cells into cardiomyocytes by culture with a BMP antagonist.

Applicants hereby provisionally elect Group I, which covers, according to the Restriction Requirement, claims 1-18, drawn to a method for differentiation pluripotent stem cells into cardiomyocytes by culture with a BMP antagonist, **without traverse**.

**CONCLUSION**


In view of the above remarks, early notification of a favorable consideration is respectfully requested.

Applicants believe that no fees are due in connection with this response. However, in the event that any fees are due to enter this response, the USPTO is hereby authorized to charge payment of any such fees to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

Dated: November 7, 2008

By:



Robert M. Schulman  
Registration No. 31,196

Alexander H. Spiegler  
Registration No. 56,625

HUNTON & WILLIAMS LLP  
Intellectual Property Department  
1900 K Street, N.W., Suite 1200  
Washington, D.C. 20006-1109  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)

LHP/AHS:ltm